Anti-gay activist Pastor Ken Hutcherson, who led the Referendum 71 effort to repeal Washington state's domestic partners law, has died of prostate cancer at the age of 61. Via World Net Daily: He frequently was at the center of public controversy as an opponent of homosexual activism. Show More Summary
The battle to treat prostate cancer may get more heated in 2014 as Johnson (JNJ), Medivation (MDVN) and Dendreon (DNDN) vie for market share.
In October 2012 I was diagnosed with prostate cancer. I am now cancer free. Here is my story, a detailed one, with test results.I have been taking PSA tests every couple years since 2007. It's a routine blood test recommended for men as they get older.PSA stands for Prostate Specific Antigen. Show More Summary
The methods used to anesthetize prostate cancer patients and control pain when their prostate glands are surgically removed for adenocarcinoma may affect their long-term cancer outcomes, a study led by Mayo Clinic has found.
Roswell Park Institute's Dr. Thomas Schwaab is leading 3 separate clinical studies evaluating novel immunotherapy approaches to treating kidney, bladder and prostate cancers.
Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a National Institutes of Health-supported randomized controlled clinical trial.
Scientists from the Massachusetts Institute of Technology have developed a new optical sensor that can track zinc in the body's cells, enabling researchers to learn more about its functions.Zinc is an essential mineral and is found in every tissue in the body. Show More Summary
Doctors at the North Shore-LIJ Health System have discovered that increased inflammation in the prostate may predict reduced risk for prostate cancer. The findings are published online in CANCER.Prostate cancer is one of the most common...Show More Summary
With a deluge of promising new drug treatments for advanced prostate cancer on the market, a new model of care is needed that emphasizes collaboration between urologists and medical oncologists, according to UC Davis prostate cancerShow More Summary
Scientists at the Koch Institute for Integrated Cancer Research at MIT are researching how shifts in zinc's location could be exploited for early diagnosis of prostate cancer.
Longer overall survival in patients without visceral metastases / bone complications and pain progression delayedEnzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic drug docetaxel.
James Holden submits: EDAP TMS (EDAP) could provide investors attractive gains in 2014 as a FDA decision about HIFU Ablatherm treatment for prostate cancer approaches. EDAP has been in a range between $1-$6 for the past five years with revenues being stagnant between $30 and $35 million during that time. Show More Summary
Researchers have uncovered a potential biological factor that may contribute to disparities in prostate cancer incidence and mortality between African-American and non-Hispanic white men in the United States, according to researcher...
With a deluge of promising new drug treatments for advanced prostate cancer on the market, a new model of care is needed that emphasizes collaboration between urologists and medical oncologists, according to UC Davis prostate cancer experts.
Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread. read more
UCLA researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies.Following recent studies showing that prostate cancer originates...Show More Summary
Dendreon, the maker of the the prostate cancer drug Provenge, has been marginalized by newer drugs from Johnson & Johnson, Medivation, and Astellas Pharma. What three valuable investing lessons can investors learn from Dendreon’s mistakes?
Obesity is associated with a worse prostate cancer prognosis among men whose tumors contain a specific genetic mutation, suggest results from a new study led by Harvard School of Public Health (HSPH), Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers. Show More Summary
UCLA researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies. read more
New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Researchers focus efforts on ways to recognize the tumor earlier and classify it more precisely – thereby helping avoid unnecessary operations.